Delhi High Court Rejects Vimal Elaichi Plea

The Delhi High Court has dismissed a plea filed by the makers of Vimal Elaichi, a cardamom product, seeking to quash show-cause notices issued to its brand ambassadors by the Maharashtra FDA.

The court held that the petition was non-maintainable due to lack of territorial jurisdiction, stating that courts in Maharashtra would be a more appropriate forum for the petitioner to raise its grievances.

The plea was filed by PB Agro LLP, the company behind Vimal Elaichi, which engages the services of actors such as Shah Rukh Khan, Ajay Devgn, and Tiger Shroff for promotional purposes. The company claimed that its advertisement campaign was in compliance with applicable laws.

However, the Maharashtra FDA had issued regulatory notices alleging that the advertisements for Vimal Elaichi amounted to surrogate promotion of Vimal Pan Masala, a chewable product banned in Maharashtra. The FDA had directed the actors featured in the advertisements to provide documentation demonstrating that Vimal Elaichi is a different product from the banned pan masala products.

The counsel representing the petitioner argued that the FDA notice was sent only to the actors and not to the company itself, despite the fact that the company would suffer irreparably due to any action taken by the state regulator. The counsel also stated that the petitioner was not provided with an opportunity to be heard.

The court's decision means that the brand ambassadors, including Shah Rukh Khan, Ajay Devgn, and Tiger Shroff, will still be required to respond to the FDA notices. The case highlights the importance of regulatory compliance in advertising and the potential consequences of non-compliance.

The Maharashtra FDA's actions are part of a broader effort to regulate the promotion of products that may be harmful to public health. The ban on pan masala products in Maharashtra is intended to protect consumers from the potential health risks associated with these products.

The dismissal of the plea by the Delhi High Court is a significant development in the case, and it remains to be seen how the brand ambassadors and the company will respond to the FDA notices. The case has implications for the advertising industry and the regulation of product promotion in India.

In conclusion, the Delhi High Court's decision to dismiss the plea filed by the makers of Vimal Elaichi highlights the importance of regulatory compliance and the potential consequences of non-compliance. The case is a significant development in the ongoing efforts to regulate the promotion of products that may be harmful to public health.